$Apple(AAPL)$  ggo go go

$Grab Holdings(GRAB)$  miracle pls...hehe.

Go go go $DRIV(DRIV)$ Rolls-Royce unveiled its first electric vehicle Tuesday, providing a glimpse of the century-old British carmaker’s future – to make its entire product portfolio fully-electric by 2030. The Ultra-Luxury Electric Super Coupé class car was made to still look timeless, with elements of Rolls-Royce's classic designs in addition to contemporary features of the electric era. It has two doors, four seats and an estimated range of 320 miles. The Spectre will cost somewhere between the roughly $350,000 Cullinan SUV and the $460,000 Phantom Rolls-Royce, although the carmaker hasn't specified the exact cost. Rolls-Royce expects the first customer Spectre vehicles will be delivered in late 2023. Source: usatoday.com, 19 Oct 2022

Go go go $DRIV(DRIV)$ Rolls-Royce unveils its first electric car, begins 'all-electric' goal Rolls-Royce unveiled its first electric vehicle Tuesday, providing a glimpse of the century-old British carmaker’s future – to make its entire product portfolio fully-electric by 2030. The Ultra-Luxury Electric Super Coupé class car was made to still look timeless, with elements of Rolls-Royce's classic designs in addition to contemporary features of the electric era. It has two doors, four seats and an estimated range of 320 miles.  The Spectre will cost somewhere between the roughly $350,000 Cullinan SUV and the $460,000 Phantom Rolls-Royce, although the carmaker hasn't specified the exact cost. Rolls-Royce expects the first customer Spectre

Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15 Lyme disease continues to place a heavy burden on countries in North America and Europe, with an estimated 600,000 cases each year across both regions,” said Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research & Development at Pfizer. “As the geographic footprint of Lyme disease widens, the medical need for vaccination becomes even more imperative.We are excited to continue partnering with Valneva on the development of VLA15 and look forward to working together to progress the program with the goal of bringing forward a vaccine that could help prevent this debilitating disease.” Source: pfizer.com

$Pfizer(PFE)$ Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15 Lyme disease continues to place a heavy burden on countries in North America and Europe, with an estimated 600,000 cases each year across both regions,” said Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research & Development at Pfizer. “As the geographic footprint of Lyme disease widens, the medical need for vaccination becomes even more imperative.We are excited to continue partnering with Valneva on the development of VLA15 and look forward to working together to progress the program with the goal of bringing forward a vaccine that could help prevent this debi

$Apple(AAPL)$coins